Evidence map›Paper›PMID 40677335›Full record

ArticleKidney international reports2025

Association of Pulmonary Hypertension With Outcomes in Kidney Transplant Recipients.

Isabel G Scalia, Juan M Farina, Milagros Pereyra Pietri, Nima Baba Ali, Mohammed Tiseer Abbas, Kamal Awad, Ahmed K Mahmoud, Niloofar Javadi, Nadera N Bismee, Samy Riad and 10 more

Abstract read
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Isabel G ScaliaDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Juan M FarinaDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Milagros Pereyra PietriDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Nima Baba AliDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Mohammed Tiseer AbbasDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Kamal AwadDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Ahmed K MahmoudDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Niloofar JavadiDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Nadera N BismeeDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Samy RiadDepartment of Internal Medicine, Nephrology, Mayo Clinic, Rochester, Minnesota, USA.
Hani WadeiDepartment of Transplant Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Byron SmithDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
D Eric SteidleyDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Timothy BarryDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Robert L ScottDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Yeoungjee ChoFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
David W JohnsonFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Chadi AyoubDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Reza ArsanjaniDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Girish MourDepartment of Internal Medicine, Nephrology, Mayo Clinic, Phoenix, Arizona, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pulmonary hypertension (PHTN) in patients with kidney failure is known to be associated with increased morbidity and mortality. Despite this, there is a relative paucity of large cohort data regarding its clinical impact following kidney transplantation (KTx). Therefore, this study sought to directly evaluate the prognostic implications of pretransplant PHTN in one of the largest kidney transplant cohorts to date. Methods: This retrospective observational cohort analysis reviewed all consecutive kidney transplant recipients at three tertiary transplant centers in the United States between January 1, 2011 and September 30, 2021. Pretransplant PHTN was defined as right ventricular systolic pressure (RVSP) ≥ 35 mm Hg on transthoracic echocardiography (TTE). Clinical outcomes were compared between patients with and without pretransplant PHTN, including mortality and allograft failure (overall and censored by mortality). Results: A total of 5322 KTx recipients were included; mean age 55.2 ± 13.7 years, 58.8% male. Of these patients, 1726 (32.4%) had pretransplant PHTN. PHTN was independently associated with significantly poorer outcomes: mortality (adjusted hazard ratio [aHR]: 1.24, 95% confidence interval [CI]: 1.06-1.45, Conclusion: Pretransplant PHTN classified by echocardiographic RVSP was independently and incrementally associated with an increased risk of mortality and allograft failure post-KTx. In pretransplant work up, this may allow for identification of a high-risk cohort that could benefit from further evaluation, early intervention, and closer surveillance in the posttransplant period.

Indexed as

allograft survivalkidney transplantoutcomespatient survivalpulmonary hypertension

Identifiers

PMID40677335
PMCPMC12266207

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.